SCHEMBL1015332

SCHEMBL1015332

COC(=O)c1cc(Cl)ccc1NC(=O)COCC(=O)Nc1cccc(-c2c(C)noc2C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.52
HDAC1 Q13547 1/20 0.52
AKR1C3 P42330 3/20 0.43
BRD2 P25440 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CREBBP Q92793 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
SERPINE1 P05121 1/20 0.42
FTO Q9C0B1 3/20 0.41
BRD3 Q15059 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
THRB P10828 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016111 0.92 BRD4 (0.53) BRD4HDAC1AKR1C3BRD2NPSR1
SCHEMBL1015766 0.91 BRD4 (0.52) BRD4HDAC1AKR1C3BRD2NPSR1
SCHEMBL1015761 0.91 BRD4 (0.52) BRD4HDAC1AKR1C3BRD2NPSR1
SCHEMBL1015763 0.90 BRD4 (0.52) BRD4HDAC1AKR1C3BRD2NPSR1
SCHEMBL1013377 0.82 SERPINE1 (0.43) SMN1; SMN2SERPINE1MEN1KMT2ALMNA
SCHEMBL1016282 0.82 SERPINE1 (0.47) SMN1; SMN2SERPINE1MEN1KMT2ALMNA
SCHEMBL1015635 0.82 CNR1 (0.51) SMN1; SMN2SERPINE1MEN1KMT2AMAPT
SCHEMBL1016790 0.81 SERPINE1 (0.47) NPSR1SMN1; SMN2SERPINE1MEN1KMT2A
SCHEMBL1015662 0.80 SERPINE1 (0.64) NPSR1SMN1; SMN2SERPINE1MEN1KMT2A
SCHEMBL1016339 0.80 CNR1 (0.53) SERPINE1MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 BRD4 2049/4885HDAC1 278/4885AKR1C3 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.